Ledipasvir is a potent, selective hepatitis C virus (HCV) NS5A inhibitor used as part of direct-acting antiviral (DAA) therapy for the treatment of chronic hepatitis C infection. It acts on the viral NS5A protein, which is essential for HCV RNA replication and viral assembly.
Ledipasvir is commonly combined with sofosbuvir in fixed-dose antiviral therapy for eligible patients with chronic HCV infection.
Ledipasvir is a specialized antiviral pharmaceutical API requiring controlled multi-step chemical synthesis, purification and solid-state characterization.
Important quality attributes include identity, assay, related substances, stereochemical purity, water content, residual solvents, elemental impurities, polymorphic form and stability.
CAS Number: 1256388-51-8
Molecular Formula: C49H54F2N8O6
Molecular Weight: 889.00 g/mol
Drug Class: Direct-Acting Antiviral
Pharmacological Class: HCV NS5A Inhibitor
Therapeutic Class: Antiviral Agent
Therapeutic Area: Hepatology / Infectious Diseases
Ledipasvir selectively inhibits the HCV NS5A protein, a multifunctional viral protein required for efficient viral replication and assembly.
By interfering with NS5A function, ledipasvir:
Ledipasvir is generally used in combination with other direct-acting antivirals rather than as monotherapy.
Ledipasvir is used in combination antiviral regimens for the treatment of chronic hepatitis C virus infection.
It is particularly recognized as a component of the ledipasvir/sofosbuvir combination used in appropriate HCV patient populations.
Treatment suitability depends on factors such as HCV genotype, prior treatment history, liver status and applicable regulatory labeling.
Ledipasvir is a highly potent inhibitor of the HCV NS5A replication protein. NS5A inhibitors are an important component of modern DAA combinations because they target a viral protein distinct from the viral protease and polymerase.
Typical API manufacturing may involve:
Ledipasvir API quality evaluation may include:
Ledipasvir should be stored in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light. Final storage requirements should be established through validated stability studies.
Ledipasvir is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |